Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 3-fluoro4-(4-((2-(3,5-dimethylphenyl)pyrrolidin-1-yl)methyl)phenoxy)benzamide
2. Aticaprant
3. Cerc-501
4. Jnj-67953964
5. Ly2456302
1. Aticaprant
2. 1174130-61-0
3. Ly-2456302
4. Cerc-501
5. Ly2456302
6. Jspa0658
7. Jspa-0658
8. Aticaprant [usan]
9. Jnj-67953964
10. De4g8x55f5
11. Chembl1921847
12. (s)-4-(4-((2-(3,5-dimethylphenyl)pyrrolidin-1-yl)methyl)phenoxy)-3-fluorobenzamide
13. Jnj-67953964-aaa
14. 4-[4-[[(2s)-2-(3,5-dimethylphenyl)pyrrolidin-1-yl]methyl]phenoxy]-3-fluorobenzamide
15. Unii-de4g8x55f5
16. Aticaprant [inn]
17. Aticaprant (usan/inn)
18. Cerc501
19. Gtpl9194
20. Schembl2638855
21. Dtxsid90151777
22. Ex-a2610
23. Bdbm50358171
24. Mfcd22572355
25. Who 10582
26. Zinc43206677
27. Cs-6653
28. Db12341
29. Jnj67953964
30. Ly-2456302cerc-501
31. Ac-36176
32. Cerc-501; Ly-2456302
33. Hy-101718
34. D11831
35. Q18344482
36. (s)-3-fluoro-4-(4-((2-(3,5-dimethylphenyl)pyrrolidin-1yl)methyl)-phenoxy)benzamide
37. 4-[4-[[(2s)-2-(3,5-dimethylphenyl)-1-pyrrolidinyl]methyl]phenoxy]-3-fluorobenzamide
| Molecular Weight | 418.5 g/mol |
|---|---|
| Molecular Formula | C26H27FN2O2 |
| XLogP3 | 5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Exact Mass | 418.20565627 g/mol |
| Monoisotopic Mass | 418.20565627 g/mol |
| Topological Polar Surface Area | 55.6 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 584 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Narcotic Antagonists
Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)
ABOUT THIS PAGE
92
PharmaCompass offers a list of CERC-501 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right CERC-501 manufacturer or CERC-501 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred CERC-501 manufacturer or CERC-501 supplier.
PharmaCompass also assists you with knowing the CERC-501 API Price utilized in the formulation of products. CERC-501 API Price is not always fixed or binding as the CERC-501 Price is obtained through a variety of data sources. The CERC-501 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CERC-501 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CERC-501, including repackagers and relabelers. The FDA regulates CERC-501 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CERC-501 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A CERC-501 supplier is an individual or a company that provides CERC-501 active pharmaceutical ingredient (API) or CERC-501 finished formulations upon request. The CERC-501 suppliers may include CERC-501 API manufacturers, exporters, distributors and traders.
CERC-501 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CERC-501 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CERC-501 GMP manufacturer or CERC-501 GMP API supplier for your needs.
A CERC-501 CoA (Certificate of Analysis) is a formal document that attests to CERC-501's compliance with CERC-501 specifications and serves as a tool for batch-level quality control.
CERC-501 CoA mostly includes findings from lab analyses of a specific batch. For each CERC-501 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CERC-501 may be tested according to a variety of international standards, such as European Pharmacopoeia (CERC-501 EP), CERC-501 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CERC-501 USP).
